none
none

PAIN MEDS BEFORE THE ACCC AGAIN

07-12-2017
by 
in 

Just one year ago pain med brand Nurofen was slugged with a $6 million dollar fine for making false claims about pain relief; now Voltaren is under fire for the exact same issue.

The ACCC has filed formal proceedings in the Federal Court against GlaxoSmithKline and Novartis, alleging the drugmakers misled consumers in the marketing of Voltaren Emulgel and Osteo Gel pain relief products.

Osteo Gel is marketed as being formulated for treating osteoarthritis conditions, but both Voltaren and Osteo Gel contain the same active ingredient: diclofenac diethylammonium gel 11.6mg/g.

While the recommended retail price of Osteo Gel 150 is $3 more expensive than Emulgel 150g at $28.99 compared with $25.99, the ACCC said the former was found in-store at a mark-up of up to $7.50, or 33 per cent.

“We’re so disappointed that having taken the Nurofen case, with all of the publicity around it, that we find this sort of behaviour still continuing,” Mr Sims said. 

Mr Sims said if the ACCC won the case, the watchdog would be seeking an even higher penalty than against Nurofen. “If we’re successful, we’d be looking at trying to get an even stronger deterrence message out there” he said.

Mr Sims said the ACCC was also concerned that the products were targeted at older consumers. “We’re always concerned with conduct that affects consumers who could be seen as slightly more vulnerable,” he said.

“What was happening here is that they were saying you’ve got a product that is specifically formulated for treating osteoarthritis, particularly in the knees and fingers, and indeed saying that also it’s more effective than Emulgel.

“Our concerns were not only that consumers were paying more for Osteo Gel, but they could actually buy both products and have them in their medical cabinet, thinking they treat different things.”

GSK acquired the Voltaren brand from Novartis in 2016 but the products have been sold since 2010. In March this year, GSK amended the Osteo Gel packaging to include the statement, “Same effective formula as Voltaren Emulgel”, but the ACCC alleges the amended packaging is also likely to be misleading.

Related news & editorials

  1. ETA’s warehouse has extensive Bonfiglioli stock
    11.01.2018
    11.01.2018
    by      In
    Bonfiglioli’s partnership with its largest Australian distributor, Engineering Transmission Agencies (ETA), brings quality, reliability and performance to Queensland and Northern NSW customers in industries such as mining, manufacturing, bulk materials handling, food and beverage, water and waste.... Read More
  2. Australian flag
    11.01.2018
    11.01.2018
    by      In
    It’s official: Australia is an Innovation Champion. That is the view of the US Consumer Technology Association, which launched its inaugural International Innovation Scorecard at the Consumer Electronics Show in Las Vegas.
    The scorecard is a development from the association’s annual ranking of US... Read More
  3. 10.01.2018
    10.01.2018
    by      In
    Australian company CST Wastewater Solutions has put together an environmentally friendly and cost-efficient wastewater treatment system for smaller, remote and ecologically sensitive community, municipal, agribusiness and industrial applications throughout the Asia-Pacific region.
    The two-stage... Read More
  4. 10.01.2018
    10.01.2018
    by      In
    US-based utility-scale solar power specialist SolarReserve has received development approval for its Aurora Solar Energy Project in South Australia.
    The project is located on farmland 30km north of Port Augusta and is centred on a 150MW solar thermal power station with 1100MWh of molten salt energy... Read More